Palo Alto Investors, LLC
Q1 2014 13F-HR Holdings
Net value change ($000)
+136,805
(12.8%)
New positions
4
Sold out positions
3
Turnover %
4.0%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| INTERMUNE INC | 91,630 | 162.9% |
| AUXILIUM PHARMACEUTICALS | 30,363 | 30.0% |
| CELLADON CORP | 17,779 | NEW |
| VNDA | 12,060 | 30.0% |
| ALIMERA SCIENCES INC | 11,596 | 67.9% |
| OREXIGEN THERAPEUTICS INC | 10,849 | NEW |
| QUESTCOR PHARMACEUTICALS INC COM | 10,459 | 19.9% |
| CUBIST PHARMACEUTICALS INC | 8,138 | 8.8% |
| PRTA | 6,164 | 43.3% |
| RIGL | 5,189 | 34.9% |
Top Reduces (Value $000, Stocks/ETFs)
| UTHR | -20,341 | -16.4% |
| CYBERONICS | -15,975 | -12.5% |
| ABIOMED INC | -14,512 | -20.2% |
| VIROPHARMA INC | -14,502 | -100.0% |
| AMAG | -11,524 | -26.9% |
| MOMENTA PHARMACEUTICALS INC | -5,142 | -25.1% |
| STAA | -3,278 | -6.3% |
| BMRN | -1,272 | -2.4% |
| FOLD | -1,199 | -12.7% |
| AVEO PHARMACEUTICALS, INC. | -478 | -18.3% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|